Vor Biopharma (NASDAQ:VOR) Given Buy Rating at HC Wainwright

Vor Biopharma (NASDAQ:VOR)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $31.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 118.46% from the company’s current price.

VOR has been the subject of several other reports. Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wedbush raised their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Price Performance

Shares of NASDAQ VOR traded down $0.44 during mid-day trading on Monday, hitting $14.19. 387,974 shares of the company were exchanged, compared to its average volume of 992,033. The stock has a 50 day simple moving average of $15.11 and a 200-day simple moving average of $14.13. Vor Biopharma has a 1-year low of $3.30 and a 1-year high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Sell-side analysts forecast that Vor Biopharma will post -3.56 EPS for the current year.

Insider Activity

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. The trade was a 11.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 3,002,903 shares of company stock worth $49,412,176. Insiders own 0.45% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VOR. Goldman Sachs Group Inc. raised its position in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vor Biopharma during the 1st quarter worth approximately $140,000. XTX Topco Ltd acquired a new position in Vor Biopharma in the 2nd quarter valued at about $66,000. BNP Paribas Financial Markets raised its stake in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Vor Biopharma in the 3rd quarter valued at about $230,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).